News

Biopharmaceutical company Lilly will build four new manufacturing sites across the U.S., it announced Wednesday at a Washington, D.C., press conference. The event was attended by NAM President and CEO Jay Timmons, Commerce Secretary Howard Lutnick, National Economic Council Director Kevin Hassett, Indiana Sen. Todd Young and Lilly Executive Vice President and President of Manufacturing Operations (and NAM board member) Edgardo Hernandez, among others.

What’s going on: Three of the planned manufacturing campuses will focus on producing active pharmaceutical ingredients, reshoring “critical capabilities of small molecule synthesis and further strengthening Lilly’s supply chain,” the company said in a press release. The fourth site will “extend [Lilly’s] global parenteral manufacturing network for future injectable therapies.”

• The investment in the four sites will bring Lilly’s total U.S. capital expansion commitment to more than $50 billion since 2020.
• Lilly—which in recent years has made $23 billion worth of investments in new research and manufacturing sites in the American South and Midwest—is in talks with several states about building the facilities there, but it is accepting additional expressions of interest from states until March 12.

The anticipated benefit: The four sites are expected to create more than 3,000 permanent skilled jobs and more than 10,000 construction jobs during building, according to the company.
 
The tax reform factor: Lilly’s planned expansion reflects “decades of research and dedication,” Timmons said at the event announcing the investment. It “is the culmination of sustained planning made possible by the certainty created through smart public policy—particularly the 2017 tax reforms that President Trump … championed back at a meeting of the NAM Board of Directors in September 2017.”

• Many of those manufacturing-critical reforms have been allowed to expire, however, and others will expire at the end of the year—unless Congress acts, and soon, Lilly Chair and CEO David Ricks said.
• “The Tax Cuts and Jobs Act legislation passed in 2017 during President Trump’s first term in office has been foundational to Lilly’s domestic manufacturing investments, and it is essential that these policies are extended this year.”

Keep the momentum going: Lilly’s announcement shows other manufacturers “exactly why [they] have reason for optimism and confidence,” Timmons went on. “But to keep this momentum going—to encourage more groundbreaking investments, more job creation and more life-changing innovation—a comprehensive manufacturing strategy must become the reality … because when manufacturing wins, America wins.”